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COMMENTARY
The epigenome of synovial fibroblasts: an
underestimated therapeutic target in rheumatoid
arthritis
Mojca Frank-Bertoncelj and Steffen Gay*
Abstract
Perturbed epigenetic landscape and deregulated microRNA networks are central to the permanent activation and
aggressiveness of synovial fibroblasts in rheumatoid arthritis. Current anti-cytokine therapies, although effectively
halting synovitis, cannot reverse the stably activated destructive phenotype of rheumatoid arthritis synovial fibroblasts,
offering rather limited protection against ongoing joint destruction in rheumatoid arthritis. Targeting the deregulated
epigenome of rheumatoid arthritis synovial fibroblasts is key to developing joint-protective strategies in rheumatoid
arthritis. To date, different pathogenic mechanisms have been identified that can profoundly impact the epigenetic
derangements in rheumatoid arthritis synovial fibroblasts, including increased consumption of S-adenosylmethionine,
a principal methyl donor in DNA methylation reactions, together with deregulation of crucial DNA- and histone-
modifying enzymes. Re-establishing globally disturbed DNA methylation patterns in rheumatoid arthritis synovial
fibroblasts by supplementing S-adenosylmethionine while preventing its leakage into polyamine cycles may be
a promising therapeutic strategy in rheumatoid arthritis and the first epigenetic treatment to target rheumatoid
arthritis synovial fibroblasts at the scene of the crime. Given the dynamic nature and reversibility of epigenetic
modifications, their involvement in human diseases and recent perspectives on epigenetic therapies in cancer,
epigenetic targeting of rheumatoid arthritis synovial fibroblasts should be within future reach.
Rheumatoid arthritis (RA) is characterized by inflamma-
tion and progressive destruction of joints, resulting in
pain and functional disability. Resident synovial cells,
RA synovial fibroblasts (RASF), are major effectors of
joint destruction and active contributors to joint inflam-
mation [1]. The aggressive, invasive phenotype of RASF
appears early in RA as a consequence of stable cell acti-
vation. Several key factors in the pathogenesis of RA,
including proinflammatory cytokines, innate immunity
and matrix-degradation products, critically amplify acti-
vation of RASF [2]; it remains unclear, however, whether
they are also indispensable to early cell activation.
The altered epigenome, including DNA methylation
and histone modifications, together with deregulation of
several microRNAs, is critical for establishing and stabi-
lizing the activated phenotype of RASF [3,4]. The
dynamic nature of epigenetic modifications, as described
by Adrian Bird, ‘to register, signal or perpetuate altered
activity states’ through ‘the structural adaptations of
chromosomal regions’ [5] allows RASF to adapt their
gene expression to the highly reactive microenvironment
of the rheumatoid synovium. Furthermore, the inherent
heritability of DNA and histone epigenetic marks
through cell division ensures that, once activated, RASF
remain permanently imprinted and thus independent of
the inflammatory milieu, as shown in vivo in the severe-
combined immunodeficiency mouse co-implanted with
human cartilage and RASF [1,2].
Current disease modifying and anti-cytokine therapies,
despite effectively halting or slowing inflammation and
progression of RA, offer rather limited protection against
ongoing joint destruction, with a substantial number of
patients responding inadequately or not at all. Although
these treatments can dampen the destructivity of RASF,
reversing the activated phenotype of RASF remains
unaccomplished; almost as a rule, arthritis flares up after
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discontinuing treatment and a cure for RA has not been
found (yet).
Targeting RASF is key to developing joint-protective
strategies in RA. Researchers are acutely aware of this,
as exemplified by great interest in the American College
of Rheumatology 2012 basic research conference on
fibroblasts in rheumatic diseases. The extent to which
epigenetic aberrations affect the activation of RASF,
coupled with their dynamic nature and reversibility,
makes them promising therapeutic targets, not only in
cancer [6], but also in RA. Restoring the altered epige-
netic patterns early in the pathogenesis of disease may
prove effective in precluding the development of more
chronic and aggressive disease. For example, we have
shown that the promoter of a chemokine (C-X-C motif )
ligand 12 (CXCL12) is hypomethylated in RASF, resul-
ting in increased production of CXCL12 and CXCL12-
dependent upregulation of matrix-degrading enzymes -
matrix metalloproteinases (MMPs) [7]. Early structural
changes in cartilage are required for the attachment and
invasion of RASF [8] and cartilage damage seems neces-
sary for RASF-mediated spreading of arthritis to
unaffected joints [2]. Since RASF are the major synovial
source of MMPs, it is imperative that restoring CpG
methylation of the CXCL12 promoter by epigenetic
treatments would decelerate the vicious cycle of progres-
sive joint destruction in RA. Recently, several other aber-
rantly methylated genomic loci were identified in RASF
genes regulating inflammation, extracellular matrix
interaction, cell adhesion and migration [9], substan-
tiating the role of defective DNA methylation in the
pathogenesis of RA. Additionally, the RASF genome is
globally hypomethylated [10]. As a consequence, the en-
dogenous retroviral long interspersed element 1 is reac-
tivated in RASF and can be detected in the synovial
lining and at sites of cartilage invasion, the hot spots of
active disease [3,10]. We have shown that a relative defi-
ciency of DNA methyltransferase 1 in proliferating
RASF, which can be further worsened by proinflamma-
tory cytokines, contributes to the global loss of CpG
methylation through cell division of RASF [10]. Further-
more, the consumption of S-adenosylmethionine, a prin-
cipal methyl donor in DNA methylation, is significantly
accelerated in RASF due to increased activity of spermi-
dine/spermine N1-acetyltransferase and enhanced poly-
amine recycling [11]. Supplementing S-adenosylmethionine
with a concomitant inhibition of spermidine/spermine
N1-acetyltransferase may therefore represent a promising
therapeutic approach in RA and is the first epigenetic
strategy to directly act on RASF. As a proof of principle,
targeting the globally deregulated DNA methylation has
shown effective anti-cancer potential; namely, 5-azacytidine
and 5-aza-2-deoxy-cytidine, both inhibitors of DNA
methyltransferases, are clinically approved epigenetic
drugs for treating high-risk myelodisplastic syndrome,
counteracting DNA hypermethylation in cancer cells [6].
Beside deregulated DNA methylation, altered patterns
of histone modifications can be found at the promoters
of key genes in RASF, including secreted frizzled-related
protein 1, which regulates Wnt signaling [12]. Further-
more, histone modifying enzymes, specifically the his-
tone methyltransferase enhancer of zeste homolog 2 and
histone deacetylases (HDACs), which are responsible for
depositing and removing epigenetic marks, are misregu-
lated in RASF and proinflammatory cytokines potentiate
this misregulation [3,12]. Despite the complexity of his-
tone acetylation, pan-inhibitors of HDACs (HDACi)
have demonstrated impressive pre-clinical and clinical
anti-cancer activities, reflected by their anti-proliferative,
differentiation-inducing and pro-apoptotic effects in
cancer cells, and are currently approved for the treat-
ment of cutaneous T cell lymphoma [6]. HDACi have
also consistently showed success in alleviating inflamma-
tion and preventing joint destruction, as prophylactic
and therapeutic regimens, in several rodent models of
arthritis [3]. Nevertheless, histone-modifying enzymes,
including HDACs, can target several other non-histone
proteins, such as transcription factors like nuclear factor
kappa B (NF-κB), that are central to the pathogenesis
of RA [3,13]. The anti-arthritic effects of HDACi
should therefore be carefully interpreted in terms of
restoring histone acetylation patterns in RASF. In this
regard, several histone-unrelated anti-inflammatory
mechanisms of HDACi have recently been demon-
strated in RASF, including inhibition of nuclear reten-
tion of NF-κB and acceleration of interleukin-6
mRNA decay [13].
Deregulated microRNA networks add another level to
the complexity of the activation of RASF. MicroRNA-
203 is overexpressed in RASF, enhancing the secretion
of MMP-1 and interleukin-6 [4]. Tumor necrosis factor-
α-induced microRNA-18a activates RASF through a
feedback loop in NF-κB signaling [14]. Furthermore,
microRNA-155 plays a proinflammatory role in clinical
and experimental arthritis, and microRNA-155-deficient
mice are resistant to collagen-induced arthritis, sugges-
ting microRNA-155 as an intriguing therapeutic target
in RA [15].
Conclusion
Targeting RASF by epigenetic agents provides a rationale
for new therapeutic strategies in RA. Given the dynamic
plasticity of the epigenome, the rapidly increasing know-
ledge in the field of epigenetics, and the recent imple-
mentation of epigenetic drugs in cancer treatment,
epigenetic targeting of RASF appears to be within future
reach.
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